iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Core Insights - iBio, Inc. is hosting a corporate update call on March 17, 2026, to discuss its strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) [1] - The company is developing a selective bispecific antibody targeting Activin A, GDF8 (myostatin), and GDF11 to address cardiac fibrosis and improve functional capacity, filling a gap in current PH-HFpEF therapies [2][3] - iBio aims to declare its optimized bispecific antibody development candidate for PH-HFpEF in Q3 2026, prior to entering IND-enabling activities [2] Company Overview - iBio, Inc. is a biotech company utilizing AI and advanced computational biology to create biopharmaceuticals for cardiometabolic and cardiopulmonary diseases, among others [7] - The company focuses on developing breakthrough antibody treatments to meet significant unmet medical needs, particularly in cardiometabolic diseases [7] Disease Context - Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome affecting approximately half of all heart failure cases, often linked to obesity, diabetes, hypertension, and aging [5] - PH-HFpEF is a severe subtype associated with pulmonary vascular remodeling and poor prognosis, highlighting the need for more effective treatments [5] Bispecific Antibody Program - iBio's bispecific antibody program targets myostatin (GDF8), GDF11, and Activin A, which are crucial for skeletal muscle health and metabolic function, potentially addressing both obesity-related dysfunction and PH-HFpEF [6]